(Q37075939)

English

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

scientific article published on 15 March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

randomized controlled trial

1 reference

based on heuristic

inferred from title

object named as

Linda Davies

3

0 references

object named as

Peter B Jones

9

0 references

object named as

Robin M Murray

4

0 references

Thomas R E Barnes

2

object named as

Thomas R E Barnes

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Shôn W Lewis

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Graham Dunn

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Karen P Hayhurst

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Alison Markwick

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Helen Lloyd

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

15 March 2006

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Schizophrenia Bulletin

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

715-723

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Covariate adjustment in clinical trials with non-ignorable missing data and non-compliance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

A systematic review of atypical antipsychotic drugs in schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Optimal dosing of atypical antipsychotics in adults: a review of the current evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Strengthening clinical effectiveness trials: equipoise-stratified randomization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Risperidone versus other atypical antipsychotic medication for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Newer atypical antipsychotic medication versus clozapine for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Measures of quality of life among persons with severe and persistent mental disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

29 September 2017

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

27 June 2018

Evaluation of treatment-resistant schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

27 June 2018

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

27 June 2018

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

27 June 2018

A rating scale for extrapyramidal side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

27 June 2018

Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

4 September 2018

Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

4 September 2018

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

4 September 2018

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632262

4 September 2018

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

1 reference

https://pubmed.ncbi.nlm.nih.gov/16540702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16540702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/16540702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16540702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A depression rating scale for schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/16540702

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/SCHBUL/SBJ067

1 reference

https://api.fatcat.wiki/v0/release/5lxtjfvk4jco5jg5jfgwmq3spy

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_5lxtjfvk4jco5jg5jfgwmq3spy

1 reference

https://api.fatcat.wiki/v0/release/5lxtjfvk4jco5jg5jfgwmq3spy

30 July 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

https://api.fatcat.wiki/v0/release/5lxtjfvk4jco5jg5jfgwmq3spy

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/5lxtjfvk4jco5jg5jfgwmq3spy

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37075939&oldid=2150896429"